Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, today announced the launch of DORA Community Edition, a free, self-hostable version of its comprehensive AI platform for Scientific Research and Content Creation. Initiated by Insilico and supported by Microsoft, DORA Community Edition aims to democratize access to state-of-the-art research tools, foster global collaboration, enhance transparency of scientific research, and accelerate innovation across biotechnology and academic landscapes.
In an era of rapid scientific advancement, the process of documenting research—from scientific and literature reviews to patent applications and business reports—can be a time-consuming task.
DORA emerged alongside the rise of LLM applications in July 2024. Developed by Insilico, it is an advanced Agentic AI-driven tool designed to streamline the drafting of academic papers and other research-related documents. It helps researchers create a variety of professional-grade documents and provide accurate references using a team of agile AI agents, engineered prompts, pre-designed content-generation workflows and Insilico's proprietary databases.
The company recently completed a new upgrade to DORA’s capabilities, supported by Microsoft and powered by Microsoft Foundry. These upgrades enable DORA to seamlessly integrate with various Foundry models, including the top-tier O3 Deep Research, significantly enhancing the tool’s research efficiency and quality.
The upcoming DORA Community Edition will be available under the permissive Apache 2.0 license, offering business-friendly terms for use and modification. Developers and researchers worldwide can get started with Open-Source DORA by accessing the code on GitHub: https://github.com/insilicomedicine/DORA
"We believe that the future of scientific discovery lies in collaboration, not isolation," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "By open-sourcing DORA, we are placing powerful AI tools directly into the hands of innovators everywhere. Our hope is to build a vibrant ecosystem where the community can collectively enhance research integrity, push the boundaries of what's possible in biotechnology, and ultimately bring life-saving therapies to patients faster."
“Microsoft is committed to working with partners and customers to enable and accelerate scientific discoveries that benefit people, organizations, and industries around the world,” said Elena Bonfiglioli, General Manager of Global Healthcare and Life Science at Microsoft, “We are excited to support Insilico in open sourcing DORA. “By helping researchers search, organize, and synthesize complex scientific information, DORA lowers barriers to cutting-edge research and expands access to generative AI. As a partner in the Microsoft Discovery preview, we are working together with Insilico to enable deeper scientific collaboration and supporting customers in applying AI to deliver meaningful, human-centered impact.”
In addition to DORA Community Edition, Insilico offers a more comprehensive version of DORA (SaaS) for users requiring advanced, specialized capabilities. Compared to the open-source version, DORA SaaS provides access to pre-analyzed protein–disease association reports within Insilico’s target discovery engine, PandaOmics, enabling deeper, domain-specific insights. It is also connected to Insilico’s Data Warehouse, supporting instant in-text citations. Additionally, DORA SaaS features a more extensive library of pre-designed templates to support the creation of diverse scientific content. Users can also access and deploy DORA SaaS directly through the Microsoft Marketplace.
In 2016, Insilico first described the concept of using generative AI for designing novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since then, Insilico has continued to integrate technical breakthroughs into the Pharma.AI platform, which is now a generative AI-powered solution encompassing biology, chemistry, medicine development, and scientific research.
Recently, Insilico hosted the Winter Edition of its Pharma.AI webinar, unveiling the latest updates to its software portfolio, introducing MMAI Gym for LLM training, and outlining its vision for advancing toward pharmaceutical super-intelligence. Fill in this form for on-demand access.
By integrating the technologies of AI and automation, Insilico has demonstrated a significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com